Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

21 January 2020

Pharma is making some effort to fight superbugs, but progress is ‘patchy’

Covering the latest results of the Antimicrobial Resistance Benchmark, Ed Silverman of STAT reports on where companies are taking action, and where gaps remain.

Direct links

Read the full article

The article begins with a snapshot of company progress in areas such as AMR surveillance and the prevention of overselling. It then zooms in on R&D pipelines describing the marginal increase in the number of antibiotics being developed since 2018. 

The article compares the findings of the Benchmark to reports issued previously by the World Health Organization, which reached similar conclusions about the overall lack of private investment and innovation in antibiotic development. 

The article then looks at some of the potential solutions to encourage and incentivise innovative antibacterial R&D for antibacterial and antifungal medicines with quotes from Jayasree Iyer, Executive Director of the Access to Medicine Foundation, Thomas Cueni, of the International Federation of Pharmaceutical Manufacturers & Associations and Glyn Edwards, Chief Executive Director at Summit Therapeutics. 

It concludes with a summary of the Benchmark Key Findings in antibacterial R&D, progress in responsible promotion, and tracking the spread of resistance.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved